Clinical Trials

Sponsor: MUSC

Sponsor Study ID: 103909

Study Title: A Phase II study of Fingolimod in Patients with Non-Small Cell and Small Cell Lung Cancer

CTO #: 103909

NCT Number:

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Lung

Study Objectives: To determine the safety and tolerability of fingolimod in patients with NSCLC and SCLC. To evaluate the objective response rate (ORR) (when measurable) according to RECIST 1.1 criteria



Study Documents    
(MUSC NetID required for document access)